MenB young adults vaccine coverage report up to October 2026
Updated 12 November 2026
Applies to England
This interim report presents meningococcal group B (MenB) vaccine coverage in England for the one-off MenB programme targeting young adults, which began on 20 July 2026. This report measures coverage of dose 1 and 2 in the 2025/26 Year 13 cohort only (those born between 1 September 2007 and 31 August 2008). Coverage estimates in this report include vaccinations given from 20 July to 31 October, 2026.
Coverage is grouped by commissioning region, Integrated Care Board (ICB), Index of Multiple Deprivation decile (IMD), ethnicity and sex.
Reports in this series will be monthly and the next report will be published on 10 December 2026.
Main findings
The main findings are that up to 31 October 2026:
- coverage of dose 1 was 28.2% (228,297 vaccinated out of 809,957 eligible individuals)
- coverage of dose 2 was 19.4% (157,169 vaccinated out of 809,957 eligible individuals)
- of those vaccinated with dose 1, 68.8% (157,169 out of 228,297) had received their second dose
- coverage is gradually increasing as individuals have more time to be vaccinated
- coverage varies substantially by geography, sex, deprivation and ethnicity
Note. Individuals are only eligible to receive their second dose 28 days after they have received their first dose.
Coverage in England
Coverage up to 31 October 2026 was:
-
28.2% (228,297 vaccinated out of 809,957 eligible individuals) for dose 1 (Figure 1)
-
19.4% (157,169 vaccinated out of 809,957 eligible individuals) for dose 2
Figure 1. MenB dose 1 and 2 coverage trends, up to 31 October 2026
Coverage by geography
The main findings for coverage by geography were that:
- coverage of dose 1 by commissioning region differed by 11.4 percentage points, from 21.8% in the London region to 33.2% in the South East and South West region (Table 1)
- coverage of dose 2 by commissioning region differed by 9.8 percentage points, from 13.4% in the London region to 23.2% in the South East region (Table 1)
- coverage of dose 1 by integrated care board differed by 19.4 percentage points, from 17.1% in North East London ICB to 36.5% in Nottingham and Nottinghamshire ICB (Figure 2)
- coverage of dose 2 by integrated care board differed by 15.5 percentage points, from 9.9% in North East London ICB to 25.4% in Nottingham and Nottinghamshire ICB (Figure 3)
Table 1. MenB dose 1 and 2 coverage by commissioning region, up to 31 October 2026
| Commissioning region | MenB dose 1 coverage (%) | MenB dose 2 coverage (%) |
|---|---|---|
| North East and Yorkshire | 28.7 | 20.3 |
| North West | 25.0 | 17.3 |
| Midlands | 27.4 | 19.0 |
| East of England | 30.7 | 21.9 |
| South East | 33.2 | 23.2 |
| London | 21.8 | 13.4 |
| South West | 33.2 | 23.0 |
| Total | 28.2 | 19.4 |
Figure 2. MenB dose 1 coverage by ICB up to 31 October 2026
Figure 3. MenB dose 2 coverage by ICB up to 31 October 2026
Coverage by deprivation
The main findings for coverage by deprivation were that:
- coverage of dose 1 by IMD decile differed by 34.3 percentage points, from 12.5 in decile 1 (most deprived) to 46.8 in decile 10 (least deprived) (Table 2)
- coverage of dose 2 by IMD decile differed by 26.8 percentage points, from 7.5 in decile 1 (most deprived) to 34.3 in decile 10 (least deprived)
Table 2. MenB dose 1 and 2 coverage by IMD 2025 decile, up to 31 October 2026
| IMD decile | MenB dose 1 coverage (%) | MenB dose 2 coverage (%) |
|---|---|---|
| 1 (most deprived) | 12.5 | 7.5 |
| 2 | 16.8 | 10.4 |
| 3 | 21.5 | 13.8 |
| 4 | 24.5 | 16.4 |
| 5 | 28.8 | 19.8 |
| 6 | 30.2 | 20.8 |
| 7 | 32.9 | 22.8 |
| 8 | 34.6 | 24.3 |
| 9 | 41.0 | 29.9 |
| 10 (least deprived) | 46.8 | 34.3 |
| Total | 28.2 | 19.4 |
Coverage by ethnicity
The main findings for coverage by ethnicity were that:
- coverage of dose 1 by ethnic group differed by 36.8 percentage points, from 9.4% in the Gypsy or Irish Traveller ethnic group to 46.2% in the Chinese ethnic group (Table 3)
- coverage of dose 2 by ethnic group differed by 26.1 percentage points, from 6.2% in the Gypsy or Irish Traveller ethnic group to 32.3% in the Chinese ethnic group
Table 3. MenB dose 1 and 2 coverage by ethnic group, up to 31 October 2026
| Ethnic group | MenB dose 1 coverage (%) | MenB dose 2 coverage (%) |
|---|---|---|
| Gypsy or Irish Traveller | 9.4 | 6.2 |
| Unknown | 13.1 | 8.0 |
| Asian or Asian British – Pakistani | 14.6 | 8.4 |
| Arab | 15.9 | 8.6 |
| Black or Black British – Caribbean | 17.6 | 10.7 |
| Asian or Asian British – Bangladeshi | 19.1 | 11.3 |
| Black or Black British – Any other Black background | 22.9 | 13.0 |
| Mixed – White and Black Caribbean | 20.1 | 13.1 |
| Other ethnic groups – Any other ethnic group | 21.3 | 13.6 |
| Black or Black British – African | 27.1 | 14.9 |
| White – Other | 23.8 | 15.9 |
| Mixed – White and Black African | 29.0 | 17.4 |
| Asian or Asian British – Any other Asian background | 29.9 | 18.4 |
| White – Irish | 28.6 | 19.1 |
| Mixed – Any other mixed background | 29.1 | 19.4 |
| White – British | 33.4 | 24.0 |
| Asian or Asian British – Indian | 39.0 | 26.0 |
| Mixed – White and Asian | 37.1 | 26.6 |
| Chinese | 46.2 | 32.3 |
| Total | 28.2 | 19.4 |
Note. Ethnic group was not recorded for 13.48% of eligible individuals.
Coverage by sex
The main findings for coverage by sex were that:
- coverage of dose 1 by sex differed by 10.0 percentage points, from 23.3% in male individuals to 33.3% in female individuals (Table 4)
- coverage of dose 2 by sex differed by 7.6 percentage points, from 15.7% in male individuals to 23.3% in female individuals
Table 4. MenB dose 1 and 2 coverage by sex, up to 31 October 2026
| Sex | MenB dose 1 coverage (%) | MenB dose 2 coverage (%) |
|---|---|---|
| Male | 23.3 | 15.7 |
| Female | 33.3 | 23.3 |
| Total | 28.2 | 19.4 |
Note. Sex was not recorded for 0.02% of eligible individuals.
Data sources and methodology
Data for this report was extracted from the Immunisation Information System (IIS) and the number of vaccinations was calculated by aggregating individual level MenB vaccination records. The number of eligible individuals was estimated based on the IIS denominator which includes records for all individuals in the population, based on data from the Personal Demographic Service.
Indicator definitions
Coverage is defined as the proportion of those born between 1 September 2007 and 31 August 2008 (denominator) that have been vaccinated with MenB at any time since 20 July 2021 (numerator). Some individuals will have received the MenB vaccine prior to 20 July 2021, however since protection from the MenB vaccine lasts for around 5 years these individuals are still eligible for the one-off MenB programme. This definition means that coverage estimates include vaccination given as part of outbreak response, including the outbreak in Kent in 2026, and doses given as part of the one-off young adult programme. Vaccination coverage provides an indicator of overall protection in this cohort.
Dose 1 was defined as the earliest dose given after the 20 July 2021, including doses given up to 31 October 2026.
Dose 2 was defined as the earliest dose given at least 28 days after dose 1, including doses given up to 31 October 2026.
Individuals were included in the denominator if their NHS number was present in the IIS denominator, they had a valid GP code present in the IIS denominator and they had a valid residential postcode in England present in the Office for National Statistics (ONS) postcode directory.
Geography
Commissioning region and ICB were identified by linking each individual’s most recent residential postcode in IIS to the ONS Postcode directory.
IMD
Deprivation is estimated using the Index of Multiple Deprivation which estimates deprivation based on income, employment, education, health, crime, barriers to housing and services, and living environment. In this report we use the 2025 IMD decile of an individual’s residential Lower Layer Super Output Area as a proxy for deprivation. Residential LSOA was based on their residential postcode in IIS.
Ethnicity
Ethnicity is stratified based on the ONS Ethnic group classifications.
Sex
Sex is based on the latest recorded sex in the IIS denominator dataset.
Cohorts
The 2025/26 Year 13 birth cohort was defined as individuals born between 1 September 2007 and 31 August 2008, resident in England and alive at the extraction date. The number of eligible individuals was deduplicated based on NHS number.
In this report we have presented coverage figures for the 2025/26 Year 13 cohort, which will include those starting university for the first time. The data currently available does not allow first-time university entrants to be identified which means that coverage estimates cannot be stratified by eligibility group.
Background information
In 2026, a national MenB one-off vaccination programme was introduced for young adults in response to an outbreak of meningococcal disease in Kent that began in March 2026. The programme targets young people who were in Year 13 in the 2025/26 academic year and those aged under 25 starting university for the first time. These groups are at increased risk of meningococcal disease due to social mixing patterns and other risk factors. The programme began on 20 July 2026 and continues until 31 March 2027.
Eligibility
The one-off MenB programme is available in England, Scotland, Wales, Northern Ireland and the Crown Dependencies (Jersey, Guernsey, and the Isle of Man).
The cohorts eligible for the one-off MenB programme in England are:
- individuals born between 1 September 2007 and 31 August 2008
- individuals aged under 25, born on or after 21 July 2001 and starting at university for the first time, or starting further education for the first time and living at further education accommodation, in autumn 2026; this includes international students, students from the devolved administrations and Crown Dependencies, and those travelling abroad to study
Timing of vaccination
The MenB vaccination programme consists of 2 doses administered at least 28 days apart. Eligible individuals were advised to receive their first dose as soon as possible, so that the majority of those eligible could receive their second doses, and therefore be fully protected before the start of the 2026/27 academic year.
For the one-off programme which commenced on 20 July 2026, dose 1 will be offered until 31 December 2026 and dose 2 will be offered until 31 March 2027.
In England, the vaccination programme will be delivered in community pharmacies.
Related statistics
The Invasive meningococcal disease surveillance report presents data on laboratory-confirmed invasive meningococcal disease in England.
Cover of Vaccination Evaluated Rapidly (COVER) and the Provisional childhood vaccine coverage reports present vaccine coverage data for the infant MenB programme.
Limitations
There are some limitations which should be taken into account when interpreting the coverage figures presented in this report.
The residential postcode in IIS may be out of date if they have moved and their location has not been updated in PDS. This may impact some individuals in this cohort who have moved away for university and have not registered with a new GP.
Data flows mean that vaccinations administered outside England, including those given in the devolved administrations, will not be recorded within the IIS MenB vaccination dataset. This means that some vaccinations may not be captured in the numerator. Also, the IIS may not take into consideration all people who have left the country meaning the denominator is likely to be overestimated. These caveats mean that coverage is likely to be higher than the estimates presented here although the degree of under-estimation is difficult to accurately ascertain.
Feedback and contact details
If you have any feedback or questions about the information presented in this report please contact the UKHSA vaccine coverage team at menb@ukhsa.gov.uk.